23andme Holding Co (ME)

$4.92

+0.01

(+0.2%)▲

Live

Performance

  • $4.80
    $4.97
    $4.92
    downward going graph

    2.44%

    Downside

    Day's Volatility :3.42%

    Upside

    1.01%

    downward going graph
  • $4.80
    $20.40
    $4.92
    downward going graph

    2.44%

    Downside

    52 Weeks Volatility :76.47%

    Upside

    75.88%

    downward going graph

Returns

Period23andme Holding CoSector (Health Care)Index (Russel 2000)
3 Months
-46.17%
3.6%
0.0%
6 Months
-46.68%
10.2%
0.0%
1 Year
-68.81%
19.6%
0.0%
3 Years
-97.62%
16.8%
-23.0%

Highlights

Market Capitalization
116.6M
Book Value
$5.67
Earnings Per Share (EPS)
-26.2
Wall Street Target Price
40.0
Profit Margin
0.0%
Operating Margin TTM
-178.05%
Return On Assets TTM
-25.77%
Return On Equity TTM
-154.21%
Revenue TTM
199.2M
Revenue Per Share TTM
8.22
Quarterly Revenue Growth YOY
-33.6%
Gross Profit TTM
132.9M
EBITDA
-235.1M
Diluted Eps TTM
-26.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.1
EPS Estimate Next Year
-0.67
EPS Estimate Current Quarter
-0.22
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for 23andme Holding Co(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 713.01%

Current $4.92
Target $40.00

Company Financials

FY19Y/Y Change
Revenue
440.9M
-
Net Income
-183.5M
-
Net Profit Margin
-41.63%
-
FY20Y/Y Change
Revenue
305.5M
↓ 30.72%
Net Income
-289.3M
↑ 57.63%
Net Profit Margin
-94.71%
↓ 53.08%
FY21Y/Y Change
Revenue
243.9M
↓ 20.15%
Net Income
-183.4M
↓ 36.62%
Net Profit Margin
-75.17%
↑ 19.54%
FY22Y/Y Change
Revenue
271.9M
↑ 11.47%
Net Income
-217.5M
↑ 18.61%
Net Profit Margin
-79.99%
↓ 4.82%
FY23Y/Y Change
Revenue
299.5M
↑ 10.15%
Net Income
-311.7M
↑ 43.3%
Net Profit Margin
-104.06%
↓ 24.07%
FY24Y/Y Change
Revenue
219.6M
↓ 26.66%
Net Income
-666.7M
↑ 113.92%
Net Profit Margin
-303.55%
↓ 199.49%
Q1 FY23Q/Q Change
Revenue
92.4M
↑ 38.0%
Net Income
-64.1M
↓ 30.3%
Net Profit Margin
-69.39%
↑ 67.99%
Q2 FY23Q/Q Change
Revenue
60.9M
↓ 34.11%
Net Income
-104.6M
↑ 63.23%
Net Profit Margin
-171.9%
↓ 102.51%
Q3 FY23Q/Q Change
Revenue
50.0M
↓ 17.85%
Net Income
-75.3M
↓ 28.06%
Net Profit Margin
-150.54%
↑ 21.36%
Q4 FY23Q/Q Change
Revenue
44.7M
↓ 10.5%
Net Income
-278.0M
↑ 269.31%
Net Profit Margin
-621.22%
↓ 470.68%
Q1 FY24Q/Q Change
Revenue
64.0M
↑ 43.09%
Net Income
-208.8M
↓ 24.87%
Net Profit Margin
-326.16%
↑ 295.06%
Q2 FY24Q/Q Change
Revenue
40.4M
↓ 36.88%
Net Income
-69.4M
↓ 66.77%
Net Profit Margin
-171.72%
↑ 154.44%
FY19Y/Y Change
Total Assets
696.7M
-
Total Liabilities
382.9M
-
FY20Y/Y Change
Total Assets
404.6M
↓ 41.92%
Total Liabilities
270.4M
↓ 29.37%
FY21Y/Y Change
Total Assets
452.1M
↑ 11.73%
Total Liabilities
1.0B
↑ 287.43%
FY22Y/Y Change
Total Assets
1.2B
↑ 154.83%
Total Liabilities
236.4M
↓ 77.44%
FY23Y/Y Change
Total Assets
942.6M
↓ 18.18%
Total Liabilities
228.7M
↓ 3.28%
FY24Y/Y Change
Total Assets
395.2M
↓ 58.08%
Total Liabilities
206.6M
↓ 9.63%
Q1 FY23Q/Q Change
Total Assets
942.6M
↓ 8.01%
Total Liabilities
228.7M
↓ 16.44%
Q2 FY23Q/Q Change
Total Assets
871.2M
↓ 7.57%
Total Liabilities
195.7M
↓ 14.41%
Q3 FY23Q/Q Change
Total Assets
801.2M
↓ 8.03%
Total Liabilities
176.0M
↓ 10.08%
Q4 FY23Q/Q Change
Total Assets
608.2M
↓ 24.09%
Total Liabilities
231.0M
↑ 31.28%
Q1 FY24Q/Q Change
Total Assets
395.2M
↓ 35.03%
Total Liabilities
206.6M
↓ 10.55%
Q2 FY24Q/Q Change
Total Assets
368.0M
↓ 6.86%
Total Liabilities
224.5M
↑ 8.66%
FY19Y/Y Change
Operating Cash Flow
-98.1M
-
Investing Cash Flow
-27.8M
-
Financing Cash Flow
344.4M
-
FY20Y/Y Change
Operating Cash Flow
-185.8M
↑ 89.33%
Investing Cash Flow
-72.8M
↑ 161.58%
Financing Cash Flow
8.8M
↓ 97.44%
FY21Y/Y Change
Operating Cash Flow
-74.3M
↓ 60.03%
Investing Cash Flow
-6.5M
↓ 91.02%
Financing Cash Flow
155.3M
↑ 1659.17%
FY22Y/Y Change
Operating Cash Flow
-166.8M
↑ 124.68%
Investing Cash Flow
-108.1M
↑ 1554.48%
Financing Cash Flow
546.0M
↑ 251.5%
FY23Y/Y Change
Operating Cash Flow
-165.4M
↓ 0.86%
Investing Cash Flow
-11.3M
↓ 89.55%
Financing Cash Flow
9.8M
↓ 98.21%
Q1 FY23Q/Q Change
Operating Cash Flow
-45.0M
↓ 276.01%
Investing Cash Flow
-3.3M
↑ 7.24%
Financing Cash Flow
2.6M
↓ 23790.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-69.4M
↑ 54.26%
Investing Cash Flow
-2.7M
↓ 18.04%
Financing Cash Flow
-114.0K
↓ 104.37%

Technicals Summary

Sell

Neutral

Buy

23andme Holding Co is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
23andme Holding Co
23andme Holding Co
-27.56%
-46.68%
-68.81%
-97.62%
-49.9%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.83%
-4.55%
7.02%
-29.06%
64.14%
Agilent Technologies Inc.
Agilent Technologies Inc.
-0.69%
3.67%
26.97%
-11.54%
83.93%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-1.42%
9.73%
30.29%
-1.1%
112.21%
Danaher Corp.
Danaher Corp.
0.45%
16.22%
34.47%
-11.7%
98.5%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-1.68%
2.31%
28.84%
-7.12%
65.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
23andme Holding Co
23andme Holding Co
NA
NA
NA
-1.1
-1.54
-0.26
NA
5.67
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.68
45.68
4.88
10.56
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
28.86
28.86
2.97
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.11
37.11
2.24
21.72
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
50.0
50.0
2.65
7.58
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.78
30.78
1.16
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
23andme Holding Co
23andme Holding Co
Buy
$116.6M
-49.9%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$37.9B
64.14%
45.68
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.9B
83.93%
28.86
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.9B
112.21%
37.11
14.69%
Danaher Corp.
Danaher Corp.
Buy
$196.4B
98.5%
50.0
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.1B
65.36%
30.78
9.39%

Insights on 23andme Holding Co

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 64.02M → 40.41M (in $), with an average decrease of 36.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -277.97M → -69.4M (in $), with an average increase of 117.0% per quarter

  • Vs DHR

    In the last 1 year, Danaher Corp. has given 33.3% return, outperforming this stock by 103.3%

  • Vs TMO

    In the last 3 years, 23andme Holding Co has experienced a drawdown of -97.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 85.9%

Institutional Holdings

  • NewView Capital Partners I, LLC

    3.84%

  • Vanguard Group Inc

    3.05%

  • Euclidean Capital LLC

    2.02%

  • Sapphire Ventures (GPE) I, L.L.C.

    1.05%

  • Millennium Management LLC

    0.98%

  • BlackRock Inc

    0.92%

Company Information

23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.

Organization
23andme Holding Co
Employees
560
CEO
Ms. Anne Wojcicki
Industry
Financial

Discover More

FAQs